Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in eight FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

 

NEWSROOM

  • Jan 27

    REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa
  • Jan 26

    Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19

EVENTS

Events
  • Regeneron Pharmaceuticals Q4 2020 Earnings Conference Call
    Feb 5
    8:30 AM EST
    Feb 5, 2021 | 8:30 AM EST